##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 8 (2025)

Exacerbation of demyelinating polyneuropathy after adoptive cell therapy with tumour-infiltrating lymphocytes by metastatic melanoma

Cite this as:
Swiss Med Wkly. 2025;155:4221
Published
21.08.2025

Summary

Adoptive cell therapy (ACT) with tumour-infiltrating lymphocytes (TIL) is an effective personalised immunotherapy for patients with advanced pretreated melanoma. For TIL-ACT, tumour-specific T cells are expanded from excised tumour samples and stimulated in cell culture with interleukin-2 (IL-2). The resulting autologous tumour-infiltrating lymphocytes are reinfused to the patient after a non-myeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Thereafter, activation of tumour-infiltrating lymphocytes in the patient is supported by the administration of high-dose IL-2. Although effective, there is a need for enhancement of TIL-ACT in terms of effectiveness and toxicity. Most of the toxicity in this multistep, complex treatment regimen is due to the preparative chemotherapy and high-dose IL-2 treatment. At University Hospital Basel, we are currently evaluating an experimental approach of TIL-ACT in which we replace high-dose IL-2 by in vivo tumour-infiltrating lymphocyte activation with ANV419, a novel antibody-cytokine fusion protein consisting of IL-2 fused to an anti-IL-2 monoclonal antibody, in an ongoing phase I trial (BaseTIL-03M). The primary endpoint of the study is safety.

We herein describe the case of a patient included in the BaseTIL-03M trial with chronic inflammatory demyelinating polyneuropathy who received TIL-ACT with ANV419 and developed an acute polyneuropathy of Guillain-Barré syndrome.

References

  1. 1. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep;233(4770):1318–21. doi: https://doi.org/10.1126/science.3489291
  2. 2. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec;319(25):1676–80. doi: https://doi.org/10.1056/NEJM198812223192527
  3. 3. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994 Aug;86(15):1159–66. doi: https://doi.org/10.1093/jnci/86.15.1159
  4. 4. Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022 Dec;387(23):2113–25. doi: https://doi.org/10.1056/NEJMoa2210233
  5. 5. Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, Corral de la Fuente E, et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. J Immunother Cancer. 2023 Nov;11(11):e007784. doi: https://doi.org/10.1136/jitc-2023-007784
  6. 6. Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. Muscle Nerve. 2018 Jun;57(6):875–83. doi: https://doi.org/10.1002/mus.26028
  7. 7. Dbouk MB, Nafissi S, Ghorbani A.Neurosciences (Riyadh). Chronic inflammatory demyelinating polyneuropathy following malignant melanoma. 2012 Apr;17(2):167-70. Review.
  8. 8. Rousseau A, Salachas F, Baccard M, Delattre JY, Sanson M.J Neurooncol. Chronic inflammatory polyneuropathy revealing malignant melanoma. 2005 Feb;71(3):335-6
  9. 9. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014 Aug;10(8):469–82. doi: https://doi.org/10.1038/nrneurol.2014.121
  10. 10. Orcurto A, Hottinger A, Wolf B, Navarro Rodrigo B, Ochoa de Olza M, Auger A, et al. Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. J Immunother Cancer. 2020 Aug;8(2):e001155. doi: https://doi.org/10.1136/jitc-2020-001155
  11. 11. Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, et al. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer. 2019 Nov;7(1):296. doi: https://doi.org/10.1186/s40425-019-0759-x
  12. 12. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011 Jul;17(13):4550–7. doi: https://doi.org/10.1158/1078-0432.CCR-11-0116
  13. 13. Farook AM, Priyankara D, Aluwihare C, Mendis A. A Rare Case of Paraneoplastic Guillain-Barré Syndrome in a Patient with Endometrial Cancer. Eur J Case Rep Intern Med. 2023 Nov;10(12):004077. doi: https://doi.org/10.12890/2023_004077
  14. 14. Koike H, Sobue G. Paraneoplastic neuropathy. Handb Clin Neurol. 2013;115:713–26. doi: https://doi.org/10.1016/B978-0-444-52902-2.00041-2
  15. 15. Lehmann HC, Lopez PH, Zhang G, Ngyuen T, Zhang J, Kieseier BC, et al. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci. 2007 Jan;27(1):27–34. doi: https://doi.org/10.1523/JNEUROSCI.4017-06.2007
  16. 16. Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome. Brain. 2003 Sep;126(Pt 9):2034–42. doi: https://doi.org/10.1093/brain/awg207